Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 and \<75 years of age that meet the American College of Rheumatology (ACR) criteria for RA.~* Patients with active RA defined as:~  1. ≥3 tender joints and ≥3 swollen joints, or~ 2. DAS 28 score \>3.1~* Patients who are discontinuing treatment with either infliximab or etanercept due to:~  1. Lack of efficacy, or~ 2. Incomplete response.~* Patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab~* Those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.~Exclusion Criteria:~The following patients will not be included in the study:~* Patients who have active infections.~* Patients with latent TB. For this protocol, evidence of latent TB infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. Any suggested data on the clinical history or chest x-ray.~* Patients participating into another study or clinical trial~* Any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Non responders to other anti-TNF (Type: None): Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).